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in Carotid Artery Plaques
Martin Græbe, MD,* Sune F. Pedersen, MSC,† Liselotte Højgaard, MD, DMSC,‡
Andreas Kjær, MD, PHD, DMSC,†‡ Henrik Sillesen, MD, DMSC*
Copenhagen, Denmark
O B J E C T I V E S The objective was to evaluate inﬂammation in echolucent carotid artery plaques.
B A C KG ROUND Ultrasound echolucency of carotid artery plaques has been proven to differentiate
patients at high risk of stroke. On the other hand, positron emission tomography (PET) of plaques with
the use of [18F]-ﬂuorodeoxyglucose (FDG) identiﬁes highly inﬂamed plaques, and the combination of
molecular imaging and morphology could improve identiﬁcation of vulnerable plaques.
METHOD S A total of 33 patients with cerebrovascular symptoms and carotid artery plaques were
included prospectively for ultrasound and PET imaging. Plaque standardized gray scale medians (GSM)
were measured in longitudinal ultrasound images to quantitate echolucency, and GSM values were
compared with FDG PET uptake quantiﬁed by maximum standardized uptake values (SUV). Symptomatic
plaques were compared with contralateral carotid artery plaques considered asymptomatic, and in 17
symptomatic patients, endarterectomized plaque specimens were analyzed for CD68 expression.
R E S U L T S There was a negative correlation between GSM and FDG SUV (r  0.56, p  0.01).
Whereas echo-rich plaques tended to show low FDG uptake, echolucent plaques ranged from high to
low inﬂammatory activity, as depicted with PET. Quantitative FDG SUV differentiated asymptomatic from
symptomatic plaques, whereas GSM values did not. There was a positive correlation between CD68
expression and FDG uptake (r  0.50, p  0.04).
CONC L U S I O N S Our results substantiate previous ﬁndings of an association between plaque FDG
uptake and inﬂammation. Echolucent plaques exhibit a wide range of inﬂammatory activity, whereas
echorich plaques show little inﬂammation. FDG PET may be useful for further stratiﬁcation of echolucent
plaques being either active (vulnerable) or inactive. (J Am Coll Cardiol Img 2010;3:289–95) © 2010 by
the American College of Cardiology Foundation
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the ‡Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Denmark. The
study was funded by The Danish Heart Foundation (Copenhagen, Denmark) and The Research Fund of Rigshospitalet
(Copenhagen, Denmark). The PET/CT scanner was donated by The John and Birthe Meyer Foundation (Copenhagen,
Denmark).Manuscript received October 11, 2009; revised manuscript received January 14, 2010, accepted January 14, 2010.
S
s
c
e
n
r
s
l
c
a
e
g
s
t
t
a
a
e
fl
t
s
m
u
a
u
g
(
i
t
p
t
a
i
F
m
g
p
i
a
d
a
r
M
P
r
s
i
a
f
a
s
i
a
t
a
c
b
l
m
e
a
s
w
t
s
A
A
C
F
G
P
r
P
t
S
standardized uptake value
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 3 , 2 0 1 0
M A R C H 2 0 1 0 : 2 8 9 – 9 5
Græbe et al.
FDG PET in Atherosclerotic Carotid Plaques
290everal subgroups of both patient- and
plaque-specific risk factors have been iden-
tified in an effort to improve the stratifica-
tion of patients at risk of a primary or
econdary stroke. Besides medical treatment, the
urrent prophylactic treatment standard is carotid
ndarterectomy, which is reserved for a limited
umber of patients only, and current stratification
egimens for operation are only on the basis of the
ize of the plaque (degree of stenosis) and time since
ast neurological event, if any (1). The risk of
erebrovascular events (stroke, transitory ischemic
ttack, or eye-emboli [amaurosis fugax]) is consid-
rable in patients with carotid artery stenosis in
eneral, and the risk of a recurrent event from
ymptomatic plaques is even greater (2,3).
The distinct difference in risk profile for asymp-
omatic and symptomatic plaques probably reflects
hat vulnerable plaques are greatly overrepresented
mong symptomatic plaques. Besides inflammation,
several morphological features that can be
assessed by ultrasound characterize the vul-
nerable plaque, and one of the most substan-
tiated predictors of recurrent events is plaque
echolucency. Its use as a clinical routine
method is limited because advanced com-
puterized image standardization, used in this
study, is necessary to overcome the subjec-
tivity (4,5). It has been shown that echolu-
cent plaques are associated with an increased
risk of ipsilateral events and increased pres-
ence of plaque macrophages (6–8).
New imaging modalities are emerging,
nd positron emission tomography (PET) of ath-
rosclerosis with the use of the radiotracer [18F]-
uorodeoxyglucose (FDG), in which glucose me-
abolism within plaques can be assessed with high
ensitivity, has been suggested as a diagnostic
ethod for risk stratification (9–11). High FDG
ptake in carotid artery plaques is associated with
n abundant presence of macrophages and molec-
lar gene up-regulation of enzymes known to de-
rade the cellular matrix of vulnerable plaques
12–14). Hence, FDG PET is believed to depict
nflammation in atherosclerotic carotid lesions, and
his noninvasive molecular imaging method thus
rovides information that cannot be assessed with
he use of ultrasound.
The aim of our study was to evaluate the associ-
tion between carotid plaque ultrasound echogenic-
ty and the presence of inflammation depicted with
DG PET. To do so, results from the 2 imaging
coseodalities were compared by correlation. Plaqueene-expression of CD68, a marker of macrophage
resence, was used in a subgroup of patients to
nvestigate the association between inflammation
nd FDG uptake, and the ability of FDG PET to
iscriminate between asymptomatic and symptom-
tic plaques was used as a surrogate marker of both
isk assessment and inflammatory activity.
E T H O D S
atients. A total of 33 patients referred from neu-
ologists for carotid ultrasound investigation after
ymptoms of cerebral ischemia were prospectively
ncluded. In these patients, a total of 21 asymptom-
tic plaques and 34 symptomatic plaques were
ound. The term “plaque” is used in this report for
ll atherosclerotic lesions independent of degree of
tenosis. Eligible symptoms were stroke, transitory
schemic attack, or momentary monocular blindness
nd an ipsilateral carotid artery plaque. If a con-
ralateral plaque was present, it was included as an
symptomatic plaque. In all cases, the ipsilateral
arotid plaque was considered the reason for cere-
ral ischemia; that is, no patients had atrial fibril-
ation, and all patients underwent computed to-
ography (CT) scans to rule out intracranial
tiology for the cerebral symptoms.
Two patients had bilateral symptomatic plaques,
nd 1 had bilateral asymptomatic plaques because
ymptoms were nonhemispheric (vertigo). Patients
ere included after an overnight fast, and informa-
ion on common risk factors (age, sex, diabetes,
moking, hypertension) and medical history was
Table 1. Patient Data
Sex, male 25 (75.8)
Antihypertensive medication, yes 27 (81.8)
Current smoking, yes 13 (39.4)
Diabetes, yes 4 (12.1)
Age, yrs 68 (63.575.5)
Time since last symptom, days 46 (21.572.5)
Plasma levels 7.2 (5.88.2)
Leukocytes, billion/l 7.2 (5.88.2)
CRP, mg/l 3 (1.25.8)
Cholesterol, mmol/l 4.3 (3.54.7)
LDL, mmol/l 2.3 (1.72.6)
HDL, mmol/l 1.5 (1.21.7)
Triglycerides, mmol/l 1.1 (1.01.4)
Creatinine, mol/l 89 (71.5102.0)
Glucose, mmol/l 5.6 (5.26.2)
Scale variables are presented as median with interquartile range and cate-
gorical variables with number and percentage, n  33.
CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-B B R E V I A T I O N S
N D A C R O N YM S
T computed tomography
DG [18F]-fluorodeoxyglu
SM gray scale median
CR polymerase chain
eaction
ET positron emission
omography
UVmaxmaximumdensity lipoprotein.
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291btained, along with blood samples. Exclusion cri-
eria were insulin-treated diabetes, a blood glucose
easurement before FDG injection 8 mmol/l,
asculitis, impaired kidney function (creatinine
125 mol/l), and treatment with immunomodu-
ating or anti-inflammatory drugs due to inflamma-
ory or oncologic disease. An ultrasound investiga-
ion and a PET/CT scan were performed the same
ay. A total of 17 patients accepted carotid endar-
erectomy, which was performed the following day.
ll patients who underwent surgery had a plaque
ausing 50% stenosis and ipsilateral hemispheric
ymptoms within the past 3 months. All patients
rovided written informed consent, and the na-
ional ethics committee approved the study (ref. no.
120065513).
ltrasound. Ultrasound was performed with a linear
-3 MHz transducer on both carotid arteries (iU22
ltrasound System; Philips Ultrasound, Bothell,
Figure 1. Ultrasound and PET in Carotid Artery Disease
Examples of ultrasound imaging and [18F]-ﬂuorodeoxyglucose (FDG
a male patient (50-years-old) with moderate stenosis (50% to 60%)
tudinal ultrasound image demonstrating a heterogeneous plaque w
owing in the internal carotid artery just cranial (left) of the plaque
the fused PET/CT (middle), and FDG PET (right) reveal inﬂammation
ﬁed areas). The patient was offered surgery but declined and was dischashington). A vascular pre-setting was chosen
efore each investigation to ensure uniform record-
ngs with maximum dynamic range (60 dB), a
echanical index of 1.1, and a linear post-processing
urve. Gain was set just below visual presence of
choes in blood. B-mode digital video sequences
frame rates of 28 to 42 Hz) of the plaque were
ecorded while sweeping the plaque in longitudinal,
ircumferential, and transverse directions with and
ithout color duplex. Degree of stenosis was deter-
ined according to a Doppler assessment of peak
ystolic flow (15).
CT angiography and ultrasound video recordings
ere thoroughly compared, and 1 single ultrasound
mage representing a longitudinal cut through the
ntire length of the plaque was chosen for gray scale
edian (GSM) analysis. The image was loaded
irectly in DICOM format to imaging software
Adobe Photoshop CS4 Extended; Adobe Systems
sitron emission tomography (PET)/computed tomography (CT) in
transitory ischemic attack 13 days before investigation. (A) Longi-
a smooth surface and a gray scale median of 24. Note the shad-
esponding to calciﬁed areas also identiﬁed on the CT. (B) CT (left),
rresponding to the suspected culprit lesion (just below the calci-) po
and
ith
corr
coarged with medical treatment alone.
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292nc., Seattle, Washington) for built-in GSM mea-
urements. Image standardization was performed
y applying a black and white adjustment layer,
56-point gray scale, followed by a new curve
djustment layer where lumen was set to black,
utput 0 to 5, and transducer near adventitia to near
hite, output 185 to 195 (4). The plaque was
elineated with a freehand tool, omitting areas with
hadowing from calcified areas, and a GSM was
ead from the entire delineated area.
ET/CT. A PET/CT (Siemens BioRad 16; Siemens,
erlin, Germany) was performed 3 h after intrave-
ous injection of 400 MBq of FDG. Patients had
een fasting for at least 6 h before injection. With
he patient’s head placed in a head holder, dental
rosthesis removed, and arms aligned to the side, 3
elds of view (15 cm) PET was performed in 3
imensions for 4 min each. A low-dose CT (120
eV, 50 mAs) for attenuation correction preceded
he PET scan. After the PET acquisition, a
ontrast-enhanced (100 ml of intravenous Optiray
iodine 300 mg/ml]; Mallinckrodt Inc., Hazel-
ood, Missouri) CT arteriography was made (120
eV, 200 mAs). Images were reconstructed using
he 2-dimensional ordered subset expectation max-
mization with 8 iterations, 4 subsets, 3-mm Gaus-
ian filtering, a voxel size of 256  256  55 and
xial slice thickness of 2 mm (Siemens Navigator
orkstation, SynGo Somaris/5 software; Siemens).
0
50
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SUVmax
re 2. Association Between Echogenicity and FDG Uptake
scale median (GSM) in a single longitudinal ultrasound image
compared with FDG PET uptake, quantiﬁed with maximum stan-
ized uptake value (SUVmax), in the same carotid artery plaque.
FDG uptake was expressed as an average of all transverse PET
s (3 mm) that contained the individual plaque. The correlation
negative (r  0.556, p  0.0001), and the distribution sug-
ed that echolucent plaques exhibit different degrees of inﬂamma-
(FDG uptake), whereas echorich plaques (high GSM) showa
tively less inﬂammatory activity. Abbreviations as in Figure 1.From the CT angiography, the carotid arteries
ere identified and delineated with an oval region
f interest if plaques were present. Attenuation-
orrected PET images were fused with the CT, and
anual fusion corrections were made in 3 planes
2-dimensional orthogonal multiplanar reforma-
ions) with the use of brain, glands, vocal chords,
nd spine as anchoring points (OsiriX version 3.5.1
4-bit; OsiriX Imaging Software, Geneva, Switzer-
and). Consecutive readings of maximum standard-
zed uptake values (SUVmax) (SUVmax  maxi-
um counts in region of interest  patient weight/
ecay [time] corrected dose) were made for the
ntire plaque length (several trans-axial images) and
xpressed as a single average value.
laque gene-expression analysis. Plaques were re-
oved during carotid endarterectomy for quantita-
ive polymerase chain reaction (PCR) analysis of
D68 gene up-regulation as previously described
13). In brief, plaques were sliced transversally in
-mm slices and treated with RNALater (Applied
iosystems, Foster City, California). After RNA ex-
raction (Agilent 2100 Bioanalyzer; Agilent Technol-
gies Inc., Santa Clara, California) and reverse trans-
riptase PCR (AffinityScriptQPCR cDNA Synthesis
it; Stratagene, La Jolla, California), the quantitative
CR was performed with the use of the TaqMan
ssay (Applied Biosystems). CD68 up-regulation in
he plaques was expressed relative to mathematically
ooled reference material consisting of samples of the
uperior thyroid artery excised from the same patients
uring endarterectomy. All slices were analyzed and
veraged for each plaque.
tatistics. The GSM values and FDG uptake were
orrelated and expressed with a Spearman correla-
ion coefficient (r). A Mann-Whitney U test was
erformed as a t test between asymptomatic and
ymptomatic plaques. Because several plaques came
rom the same patient (bilateral plaques), the as-
umption of independence was violated and, there-
ore a Wilcoxon signed rank test (paired compari-
on) was included to test whether FDG uptake
iffered within a subpopulation with bilateral
laques (n  19 pairs, symptomatics with no
ontralateral plaque being excluded).
Comparisons of FDG uptake and GSM values
etween different subgroups of degree of stenosis
Fig. 4) were investigated with the use of the
ruskal-Wallis tests. The Fisher exact test was used
o test differences in degree of stenosis between
ymptomatic and asymptomatic plaques. Because
he degree of stenosis differed significantly betweenG
SM
Figu
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293nd interaction of these variables (size and symp-
oms) on FDG uptake were tested forwardly with a
nivariate F test in a general linear model with
UVmax as single dependent value. The SUVmax
ata were normally distributed, whereas GSM were
ot according to Shapiro-Wilk tests and histo-
rams. The CD68 gene expression was normally
istributed when log-transformed, and a correlation
o SUVmax was made with the use of the Pearson
orrelation. Data were presented as medians with
nterquartile ranges, and p  0.05 (2-sided) was
onsidered significant for all statistical tests. Statis-
ical calculations and graphics were made with
PSS version 16.0.1 for Mac (SPSS Inc., Chicago,
llinois) and Prism version 5.0b for Mac (GraphPad
oftware Inc., San Diego, California).
E S U L T S
ll patients had atherosclerosis and cerebrovascular
ymptoms, and therefore the entire population was
onsidered at high risk for cardiovascular disease in
eneral. Common risk factors and laboratory values
or the patients are shown in Table 1. All patients
eceived cholesterol-lowering drugs (statins) and
ntiplatelet medication at least 1 week before inclu-
ion in the study.
Comparisons of echolucency and FDG uptake
evealed that echolucent plaques exhibited a wide
ange of inflammation, whereas echorich plaques
ere depleted of PET-depicted inflammation. Ex-
mples of an ultrasound longitudinal single-slice
nd corresponding PET/CT scan from 1 patient
re shown in Figure 1, and the negative association
ound between GSM and FDG uptake (r 
0.556, p  0.0001) is shown in Figure 2.
FDG uptake was significantly lower in asymp-
omatic plaques compared with symptomatic
laques, whereas the numerical difference in GSM
as not significant (Table 2). This finding was
trengthened by a paired test including only patients
Table 2. Quantiﬁcation in Asymptomatic and Symptomatic
Plaques
SUVmax GSM
n Median (quartiles) n Median (quartiles)
Asymptomatic 21 1.847 (1.652.13) 21 24 (1430)
Symptomatic 34 2.086 (1.762.78)* 32 22 (1038)
p Value 0.041 0.610
Comparison of FDG PET (SUVmax) and ultrasound GSM characteristics of
symptomatic and asymptomatic plaques. *p  0.05 compared with asymp-
tomatic.
FDG PET [18F]-ﬂuorodeoxyglucose-positron emission tomography; GSMgray scale median; SUVmax  maximum standardized uptake value.ith bilateral plaques (n  19) that also showed
ignificant differences (p  0.023) between asymp-
omatic plaques, SUVmax  1.907 (1.714 to
.181), and symptomatic plaques, SUVmax 
.020 (1.714 to 2.335). Further evidence for the
ypothesized association between FDG uptake and
nflammation was found as FDG uptake correlated
o CD68 expression in 17 endarterectomized symp-
omatic plaques (r  0.501, p  0.041) (Fig. 3).
The GSM did not correlate to CD68 expression
p  0.153, not shown). Plaque size (degree of
tenosis) differed between asymptomatic and symp-
omatic plaques (Table 3). However, regression
nalysis showed that for all plaques together, degree
f stenosis was not an explanatory covariable for
UVmax (p  0.095), nor did it interact with
ymptoms (p  0.220) on FDG uptake values.
either significant difference in SUVmax nor GSM
alues was observed between different degrees of
tenosis (Fig. 4).
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Figure 3. Association Between FDG PET Uptake and Inﬂammato
Activity
Average macrophage speciﬁc CD68 gene up-regulation from all 3-m
slices from the endarterectomized plaque was used as a marker of
inﬂammatory activity. FDG uptake was quantiﬁed with SUVmax in a
corresponding number of transverse PET slices containing the same
plaque. Log-transformed gene upregulation was expressed relative
arterial reference tissue (0 is baseline) pooled from all patients. The
correlation was positive (r  0.501, p  0.041), suggesting that FDG
uptake depicts macrophage presence and, thus, inﬂammatory activ
Abbreviations as in Figures 1 and 2.
Table 3. Degree of Stenosis and Symptom Status
Degree of Stenosis, %
Asymptomatic,
n (%) (n  21)
Symptomatic,
n (%) (n  34)
50 14 (66.6) 3 (8.8)
5069 1 (4.8) 10 (29.5)
7099 6 (28.6) 18 (52.9)
Occluded 0 3 (8.8)
Count and column percent for different plaque size categories. Plaque size
differed signiﬁcantly between asymptomatic and symptomatic plaques, p ry
m
to
ity.0.001, in Fisher exact test.
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294I S C U S S I O N
he present data support a role for PET scans in
otentially discriminating patients with echolucent
arotid artery plaques into further risk strata. There
as a negative correlation between GSM and FDG
ptake in carotid artery plaques, and as seen in
igure 2, the main proportion of echorich plaques
high GSM) tended to show low FDG uptake,
hereas echolucent plaques (low GSM) exhibited a
ide range of FDG uptake values. The positive
orrelation found between CD68 expression and
DG uptake supports previous findings, and the
vidence for the ability of FDG PET to depict
nflammation in atherosclerosis is accumulating
12–14,16).
Ultrasound has largely replaced previous conven-
ional contrast angiography and is a cost-effective
re 4. The FDG Uptake and Echogenicity in Relation to Degree
tenosis
plots of (A) FDG uptake values quantiﬁed with SUVmax and
ltrasound GSM within different groups of plaque size. No signiﬁ-
differences were observed, suggesting that inﬂammatory activity
uptake) and morphology (GSM) were independent of the
ree of stenosis. The p values are from the Kruskal-Wallis test.
ian, quartiles, and ranges (whiskers) are shown. Abbreviations as
igures 1 and 2.ay of screening patients. It supplies the reader tith information about the degree of stenosis and
laque morphology, hence stability. However, sev-
ral problems in assessing ultrasonographic plaque
orphology have prevented this imaging method
rom reaching the level of clinical decision-making.
bjectivity is hampered because the 2-dimensional
ature of the ultrasound image leaves quantification
f echolucent areas difficult, and areas are left
nattended because of the shadowing from calcified
ortions of the plaques (4,5).
Computerized standardization of the ultrasound
mages has proven to overcome some of the subjec-
ivity in morphology assessment, and the GSM
nalysis has proven to identify subgroups of patients
ith carotid plaques with a relative higher risk of
erebral events (8,17). Echolucency in plaques may
eflect lipid deposits, hemorrhage, or necrotic debris
18 –20). Although morphological traits of the
ulnerable plaque can be identified, ultrasound
oes not reveal whether the plaque is stabilizing
r actually metabolically active with inflammatory
ctivity.
Our group (13) has previously shown that the
ET-identifiable inflammation is also associated
ith molecular overexpression of enzymes known
o have a role in the degrading processes of the
laque extracellular matrix. The combination of
cholucency and high FDG uptake may thus
dentify the vulnerable plaque with high sensitiv-
ty. Considering the availability and the high
osts of PET/CT as compared with ultrasound, it
s likely that a clinical implementation of
ET/CT for identification of high-risk patients
ould supplement rather than substitute ultra-
ound morphology investigations.
In our small population, only the PET scan
emonstrated a significant difference between the
ymptomatic and the asymptomatic plaques, sug-
esting that PET is more sensitive than ultrasound
n identifying vulnerable plaques. Results from the
aired test in patients with bilateral plaques indi-
ated that plaque FDG uptake was truly plaque
ependent rather than patient dependent (greater
DG uptake on the symptomatic side). There was,
owever, a substantial overlap between the 2
roups, reflecting the limitation in using symptoms
s a surrogate marker for inflammation. This limi-
ation also was evident from the large spread in
D68 activity found within the symptomatic
laques alone. Studies that include gene expression
nalyses in plaques from asymptomatic patients are
arranted in addition to larger studies investigatingFigu
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295xpected high risk of ipsilateral stroke in patients
ith echolucent and high FDG uptake plaques.
Interobserver and intraobserver reproducibility of
oth PET and GSM have previously been investi-
ated, and the numerical values for asymptomatic
nd symptomatic plaques we found were similar to
revious reports (4,21). In our work, GSM values
ere generally low, probably reflecting the systemic
ature of atherosclerotic activity in a population in
hich all patients had recent symptoms.
O N C L U S I O N S
he use of FDG PET reveals inflammation intery plaques, echolucency on B-mode Society of Radiologide range of inflammatory activity, whereas
chorich plaques demonstrate little inflammatory
ctivity, and FDG PET may be useful for the
tratification of echolucent plaques. Larger clinical
rials will be needed to fully understand the benefit
f additional PET/CT imaging in patients with
arotid artery stenosis.
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